References
- Investopia. Business Model. 2017 Jan 01 [cited 2017 Feb 01]. Available from: http://www.investopedia.com/terms/b/businessmodel.asp
- Light DW, Kantarijian H. Market spiral pricing of cancer drugs. Cancer. 2013 Sep 03; sec. 119-3900-2 119:3900–3902.
- Prescribe International May. New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all. Prescrire International. 2016 May 31;25(171):137–139.
- Bradshaw B. Pharmaceuticals firms braced for a year of rampant M&A. The Telegraph. 2017 Jan 09. sec. A. p. 1
- Reuters. GSK and Novartis complete deals to reshape both drugmakers. 2015 Mar 02 [cited Feb 12 2017]. Available from: http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11444023/GSK-and-Novartis-complete-deals-to-reshape-both-drugmakers.html
- Bradshaw B. GlaxoSmithKline and Google’s Verily to Invest GBO540m in Joint UK Research Centre. The Telegraph. 2016 Aug 01. sec. A.p. 1.
- Buckley JW, Chiang H. Research methodology and business decisions. National Association of Accountants. 2014 Sep 01. sec. A. pp. 87–88
- Silverman D. Doing qualitative research. California US: Sage Publications. 2013 Dec 01. sec. A. 200–213.
- Mays N, Pope C. Qualitative research in health care. Assessing quality in qualitative research. BMJ. 2000 Jan 01 sec. A. 20:312–320.
- Malmström R, Godman B, Diogene E. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013 May 14 sec. A. 4–39.
- Godman B, Malmström R, Diogene E. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Rev Clin Pharmacol. 2015 Jan 8;8:77–94. sec. A.
- O’Neill J. Securing new drugs for future generations: the pipeline of antibiotics. The review on antimicrobial resistance. 2015 May 31 [cited 2017 June 14]. Available from: https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf
- The Pharmaletter. An all-time record year for pharma/biotech M&A in 2015. 2016 Jan 07 [cited 2017 Feb 11]. Available from: https://www.thepharmaletter.com/article/an-all-time-record-year-for-pharma-biotech-m-a
- Abboud C, Berman E, Cohen A. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013 Apr 23; sec. A 121(22):4439–4442.
- Dierks R, et al. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Rev Pharmacoecon Outcomes Res. 2016 Oct 05; sec. A. 1:1–6 .
- AbbVie. AbbVie to expand oncology presence through acquisition of Stemcentrx and its novel, late-stage rova-T compound for small cell lung cancer. 2016 Apr 28 [cited 2017 Feb 11]. Available from: https://news.abbvie.com/news/abbvie-to-expand-oncology-presence-through-acquisition-stemcentrx-and-its-novel-late-stage-rova-t-compound-for-small-cell-lung-cancer.htm
- Financial Times. Johnson & Johnson to buy Swiss biotech Actelion for USD 30bn. 2017 Jan 29 [cited 2017 Jan 31]. Available from: https://www.ft.com/content/b3b98348-e396-11e6-8405-9e5580d6e5fb
- The Pharmaletter. 2017 M&A outlook for mid-market pharma: dealmaking will continue to be a key growth strategy. 2016 Dec 21 [cited 2017 Feb 11]. Available from: https://www.thepharmaletter.com/article/2017-m-a-outlook-for-mid-market-pharma-dealmaking-will-continue-to-be-a-key-growth-strategy
- Hirschler B. Trump tax cuts could mean more Novartis investment in U.S. Reuters. 2017 Jan 18. sec. A. p. 1.
- BMI Research. Growth of the Global Pharmaceutical Market. Aug 5 2010 [cited 2017 Mar 25]. Available from: http://www.bmiresearch.com/searchbox